Join the RASCALS Foundation for ALS Awareness Month at the big 5K Walk and Run at Tower Grove Park in St. Louis, Sunday May 4, 2014.
While the size of this study is small, the ability of the specific biomarkers used to predict ALS prognosis suggests that the approach holds promise.
Research led by King’s College London has identified a new genetic variant, located on chromosome 17, associated with sporadic amyotrophic lateral sclerosis (ALS) – the most common form of motor neurone disease (MND).
For patients with amyotrophic lateral sclerosis (ALS), the simple act of breathing is often a tough thing to do. Now, these patients have new hope, as a device has been approved by the U.S. Food and Drug Administration (FDA) that may help patients to breathe more easily without a ventilator.
Respiratory failure is one of the major complications associated with amyotrophic lateral sclerosis (ALS). The quest for alternative approaches for treating respiratory failure has led to the study, and subsequent FDA approval, of diaphragm pacing for use in ALS patients.
“We are very excited to announce the selection of IMS-088 as ImStar’s lead ALS compound. As we continue with preclinical development next year, we hope to establish IMS-088 as a safe and effective new drug candidate for ALS,” said Jean-Pierre Julien, ImStar’s chief scientific officer.
According to a post hoc analysis, a greater percentage of patients receiving NP001 experienced a halt in disease progression which reached statistical significance when compared to the combination of concurrent and matched historical (placebo) controls. The high dose of NP001 (2mg/kg) halted progression in 27% of patients compared to 11% of patients on placebo. Further, NP001 was found to be safe and well-tolerated in the study.
The ALS Therapy Development Institute (ALS TDI), together with its wholly-owned subsidiary, Anelixis Therapeutics, announced today that it has formed a research partnership with Neurimmune to advance potential treatments for ALS, also known as Lou Gehrig’s disease.
The Robert A. Stehlin Campaign for ALS (R.A.S.C.A.L.S.) is delighted to welcome Sandra Putney to the foundation’s Board of Directors, where she will assume the duties of Treasurer. Sandra is committed to using her business acumen and leadership abilities to safeguard donor dollars while ensuring that donations are maximized for the organization’s mission.
Scientists have identified a novel therapeutic approach for the most frequent genetic cause of Amyotrophic lateral sclerosis (ALS).